Skip to main content
PharmSpace

Class Explorer · Hematology

Anticoagulants

Interrupt the coagulation cascade: warfarin starves factor synthesis upstream; DOACs inhibit factor Xa or thrombin directly.

Open the interactive pathway

Members

Also in this class: Rivaroxaban (Xa, once daily with food) · Edoxaban (Xa) · Dabigatran (IIa, dyspepsia, idarucizumab) · Heparins (parenteral, AT-mediated). Full pages arrive as the library grows.

Compare the members

Warfarin
Target
VKORC1 (II, VII, IX, X)
Monitoring
INR
Renal reliance
Minimal
Apixaban
Target
Factor Xa
Monitoring
Renal function, adherence
Renal reliance
~27%
Rivaroxaban
Target
Factor Xa
Monitoring
None routine
Renal reliance
Contraindicated at low clearance
Enoxaparin
Target
Factor Xa mainly, via antithrombin
Monitoring
Anti-Xa in selected patients
Renal reliance
Dose reduced below 30 mL/min

Shared across the class

Indications
Stroke prevention in AF · VTE treatment and prevention · Mechanical valves (warfarin only)
Adverse effects
Bleeding: the class effect that defines all counselling
Contraindications
Active major bleeding
Monitoring
Warfarin: INR · DOACs: renal function at least annually · All: bleeding signs, adherence, procedures

What makes each agent different

  • Monitoring: warfarin is INR-run; DOACs are fixed-dose with renal-function surveillance instead.
  • Onset/offset: DOACs act within hours and fade within a day or two; warfarin takes days each way.
  • Territory warfarin keeps: mechanical valves, antiphospholipid syndrome, severe renal failure (jurisdiction-dependent).
  • Reversal: vitamin K + PCC for warfarin; idarucizumab (dabigatran) and andexanet (Xa) where available.

The DOAC's freedom from INR checks silently removes the adherence check that came with them. Ask on purpose.

Last reviewed 2026-08-15 · Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.